For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Many patients will require more than 1 drug to achieve blood pressure goals. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol.Ĭontrol of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue metoprolol succinate extended-release tablets therapy abruptly even in patients treated only for hypertension ( 5.1).
Warn patients against interruption or discontinuation of therapy without the physician’s advice. If angina markedly worsens or acute coronary insufficiency develops, metoprolol succinate extended-release tablets administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. When discountinuing chronically administered metoprolol succinate extended-release tablets, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1 - 2 weeks and the patient should be carefully monitored.
* Sections or subsections omitted from the full prescribing information are not listed.įollowin abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. ( 5.11)įULL PRESCRIBING INFORMATION: CONTENTS * BOXED WARNINGħ.3 Digitalis, Clonidine, and Calcium Channel Blockersġ3.1 Carcinogenesis, Mutagenesis, Impairment of Fertility